COVID-19 impact in Crohn’s disease patients submitted to autologous hematopoietic stem cell transplantation

Table 1 Demographic and clinical characteristics of Crohn disease patients coronavirus disease 2019 + underwent autologous hematopoietic stem cell transplantation (2013-2021; 19/50 pts)

	Age (yr)	Sex	HSCT date	Elapsed months	Vaccina	Label vaccine (n)	CD status	COVID-19	Months HSCT to COVID	Vaccination at infection time	Symptoms COVID-19 +	Treatment COVID-19+	CD Status before COVID-19 pts +	CD Status after COVID-19 pts +	Delayed symptoms after COVID-19
5	41-45	F	2015	84	No	0	Remission	Yes	76	No	Fever, flu-like symptoms, cough, body aches	0	Remission	Remission	0
7	56-60	M	2015	78	Yes	(2) Az	Remission	Yes	77	Yes	Fever, body aches, fatigue	0	Remission	Remission	0
8	51-55	M	2015	77	No	0	Remission	Yes	76	No	Severe body aches, severe headache, physical and mental fatigue and diarrhea	0	Remission	Remission	Fatigue, muscle weakness, shortness of breath
12	31-35	M	2016	71	No	0	Relapsed	Yes	59	No	Flu symptoms	0	Relapsed	Relapsed	0
14	41-45	M	2016	69	Yes		Relapsed	Yes	68	Yes	Coryza and sore throat	0	Relapsed	Relapsed	0
15	51-55	F	2016	69	Yes	0	Remission	Yes	68	No	Headache, diarrhea, hospital stay 5 days	Iver, Cort e Azitro	Remission	Remission	Sleep disorders, headache
20	31-35	F	2017	57	Yes	(2) Az (1) Pf	Remission	Yes	56	Yes	Headache, rashes, fever, cough and sore throat	Azitro, Cort	Remission	Remission	Loss of taste, nausea and alopecia
22a	26-30	F	2017	55	No	0	Remission	Yes	41	No	Flu-like symptoms, nausea, fatigue	0	Remission	Remission	0
22b	26-30	F	2017	55	Yes	(2) Az	Remission	Yes	54	Yes	Cough	0	Remission	Remission	Diarrhea
24	41-45	F	2017	50	Yes	(2) Az (1) Pf	Relapsed	Yes	49	Yes	Fever, sore throat, body aches, vomiting, headache, cough and worsening diarrhea	0	Relapsed	Relapsed	Cough, headache and dizziness, burning in the throat
27	41-45	F	2018	45	Yes	(1) Az	Remission	Yes	32	No	Body ache and sore throat	Azitro, Iver	Remission	Remission	0
29	36-40	F	2018	42	Yes	(2) Az (1) Pf	Relapsed	Yes	41	Yes	Sore throat, cough, runny nose, body ache, fever, indisposition	0	Relapsed	Relapsed	0
31	36-40	M	2019	33	Yes	0	Relapsed	Yes	24	Yes	Shortness of breath, cough and asthma	Azitro, Cort	Relapsed	Relapsed	Coagnitive disorders
33	16-20	F	2019	32	No	0	Relapsed	Yes	12	No	Headache, sneezing, body ache, runny nose	0	Relapsed	Relapsed	0
34	31-35	F	2019	30	Yes	(3) Pf	Relapsed	Yes	29	Yes		0	Relapsed	Relapsed	0
40a	31-35	F	2020	24	No	0	Relapsed	Yes	6	No	Loss of taste and smell, fever, tiredness, diarrhea, sore throat, headache and body pain. Loss of taste and smell, fever, tiredness, diarrhea, sore throat, headache and body pain	0	Remission	Relapsed	Muscle weakness, sleep and cognitive disturbances with CD symptoms
40b	31-35	F	2020	24	Yes	(2) Az (1) Pf	Relapsed	Yes	23	Yes	Sore throat, cough, runny nose, fever, headache and body ache	0	Relapsed	Relapsed	Muscle weakness, sleep and cognitive disturbances with CD symptoms
41	51-55	F	2020	24	Yes	(2) Pf	Relapsed	Yes	23	Yes	Fever, body aches, sore throat and weakness	0	Relapsed	Relapsed	Diarrhoea, severe abdominal pain
43	46-50	M	2020	16	Yes	0	Relapsed	Yes	6	No	Fever, stuffy nose, loss of smell and taste, and muscle aches	0	Remission	Relapsed	0
44	36-40	M	2020	14	Yes	0	Relapsed	Yes	4	No	Fever, headache, lack of appetite, tiredness, cough, weakness	0	Remission	Relapsed	0
50	31-35	F	2021	5	Yes	(2) Az (1) Pf	Remission	Yes	3	Yes	Fever, headache, body ache, sore throat, cough, tiredness, chest pain, vomiting, diarrhea	0	Remission	Remission	0

CD: Crohn's disease; COVID-19: Coronavirus disease 2019; Azitro: Azitromycin, Cort: Corticoesteroids, F: Female; Iver: Ivermectin; HSCT: Hematopoietic stem cell transplantation; M: Male; Az: Oxford/Astra Zeneca ChAdOx1-S; Cort: Corticosteroids; F: Female; Iver: Ivermectin; M: male; Pf: Pfizer Biontech BNT16-2b2.

Table 2 General Statistics of the Crohn disease patients underwent to autologous hematopoietic stem cell transplantation and coronavirus disease 2019 (50 pts. 2013-2021), n (%)/mean ± SD

		COVID-19 positive patients, 19 (38%)	COVID-19 negative patients, 31 (62%)
Sex	Female	12 (42.85)	16 (57.14)	0.4251
	Male	7 (31.81)	15 (68.18)
Age (yr)		39.11 ± 10.104	37.52 ± 8.84	0.5622
Elapsed time HSCT until evaluation (month)		46.05 ± 24.19	48.71 ± 28.12	0.7342
Elapsed time HSCT until COVID-19 +		39.47 ± 26.57
COVID-19 vaccination	Yes	9 (23.1)	30 (76.9)
	No	10 (90.90)	1 (9.1)
CD status before COVID-19	Relapsed	8 (28.57)	20 (71.42)	0.15003
	Remission	11 (50)	11 (50)
CD status after COVID-19	Relapsed	11 (35.48)	20 (64.52)	0.76613
	Remission	8 (42.10)	11 (57.89)

¹Pearson Chi-square test.

²t-test.

³Fisher's exact test.

CD: Crohn's disease; COVID-19: Coronavirus disease 2019; HSCT: Hematopoietic stem cell transplantation.